Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 531-539

  Auvinen, Päivi ^a,b   Tammi, Raija ^b   Kosma, Veli Matti ^a,b   Sironen, Reijo ^a,b   Soini, Ylermi ^a,b   Mannermaa, Arto ^a,b   Tumelius, Ritva ^b   Uljas, Eliisa ^a   Tammi, Markku ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

breast cancer; CD44; HER2; hyaluronan; obesity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HORMONE RECEPTOR; HYALURONIC ACID;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BODY MASS; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOMA CELL; FEMALE; GENE; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; STROMA CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; HUMANS; HYALURONIC ACID; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROGNOSIS; RECEPTOR, ERBB-2; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870255943     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27707     Document Type: Article

References (49)

1. Tammi R, Kultti A, Kosma VM, et al. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008; 18: 288-95.
2. Sironen R, Tammi M, Tammi R, et al. Hyaluronan in human malignancies. Exp Cell Res 2011; 317: 383-91.
3. Auvinen P, Parkkinen J, Johansson R, et al. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997; 74: 477-81.
4. Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36.
5. Itano N, Sawai T, Atsumi F, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004; 279: 18679-87.
6. Toole BP, Zoltan-Jones A, Misra S, et al. Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs 2005; 179: 66-72.
7. Bourguignon L, Spevak C, Wong G, et al. Hyaluronan-CD44 interaction with protein kinase C(Îμ) promotes oncogenic signaling by the stem cell marker nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009; 284: 26533-46.
8. Mytar B, Siedlar M, Woloszyn M, et al. Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronan. Int J Cancer 2001; 94: 727-32.
9. Slevin M, Kumar S, Gaffney J,. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277: 41046-59.
10. Matou-Nasri S, Gaffney J, Kumar S, et al. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and Î-adducin. Int J Oncol 2009; 35: 761-73.
11. Koyama H, Kobayashi N, Harada M, et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am J Pathol 2008; 172: 179-93.
12. Turley E, Noble P, Bourguignon L,. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277: 4589-92.
13. Jalkanen S, Bargatze R, de los Toyos J, et al. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983-90.
14. Ponta H, Wainwright D, Herrlich P,. The CD44 protein family. Int J Biochem Cell Biol 1998; 30: 299-305.
15. Lokeshwar V, Iida N, Bourguignon L,. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996; 271: 23853-64.
16. Foekens JA, Dall P, Klijn JG, et al. Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 1999; 84: 209-15.
17. Joensuu H, Klemi PJ, Toikkanen S, et al. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993; 143: 867-74.
18. Toole B,. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009; 15: 7462-8.
19. Misra S, Toole BP, Ghatak S,. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 2006; 281: 34936-41.
20. Sugahara K, Hirata T, Hayasaka H, et al. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 2006; 281: 5861-8.
21. Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
22. Harari D, Yarden Y,. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-14.
23. Wang K, Kao A, Chang C, et al. Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 2010; 9: 288.
24. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009; 27: 5685-92.
25. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
26. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-44.
27. Perez E, Romond E, Suman V, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-73.
28. Ghatak S, Misra S, Toole B,. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005; 280: 8875-83.
29. Misra S, Ghatak S, Toole B,. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005; 280: 20310-15.
30. Bourguignon L, Gilad E, Peyrollier K,. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 2007; 282: 19426-41.
31. Saavalainen K, Pasonen-Seppanen S, Dunlop TW, et al. The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene. J Biol Chem 2005; 280: 14636-44.
32. Palyi-Krekk Z, Barok M, Isola J, et al. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007; 43: 2423-33.
33. Tammi R, Agren UM, Tuhkanen A, et al. Hyaluronan metabolism in skin. Prog Histochem Cytochem 1994; 29: 1-81.
34. Hamalainen K, Kosma VM, Eloranta ML, et al. Downregulated CD44 and hyaluronan expression in vulvar intraepithelial neoplasia and squamous cell carcinomas. Acta Obstet Gynecol Scand 2010; 89: 108-19.
35. Váradi T, Mersich T, Auvinen P, et al. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem, in press.
36. Duterme C, Mertens-Strijthagen J, Tammi M, et al. Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. J Biol Chem 2009; 284: 33495-508.
37. Slomiany M, Dai L, Tolliver L, et al. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 2009; 15: 7593-601.
38. Brown R, Reinke L, Damerow M, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-74.
39. Simpson M, Weigel J, Weigel P,. Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer. Int J Cancer, in press.
40. Li Y, Li L, Brown T, et al. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 2007; 120: 2557-67.
41. Urakawa H, Nishida Y, Wasa J, et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 2012; 130: 454-66.
42. Thompson C, Shepard H, O'Connor P, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010; 9: 3052-64.
43. van den Brandt P, Spiegelman D, Yaun S, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-27.
44. Jokela T, Makkonen K, Oikari S, et al. Cellular content of UDP-N-acetylhexosamines controls hyaluronan synthase 2 expression and correlates with O-linked N-acetylglucosamine modification of transcription factors YY1 and SP1. J Biol Chem 2011; 286: 33632-40.
45. Kultti A, Karna R, Rilla K, et al. Methyl-β-cyclodextrin suppresses hyaluronan synthesis by down-regulation of hyaluronan synthase 2 through inhibition of akt. J Biol Chem 2010; 285: 22901-10.
46. Sainio A, Jokela T, Tammi M, et al. Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis. Glycobiology 2010; 20: 1117-26.
47. Hsu P, Sabatini D,. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-7.
48. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012; 130: 921-9.
49. Stern R, Shuster S, Neudecker B, et al. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 2002; 276: 24-31.